Register Login

AMGEN INC (AMGN)

SymbolAMGN
NameAMGEN INC
SectorHEALTH CARE
RegionUNDEFINED
IndustryBiological Products, (No Diagnostic Substances)
AddressONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA 91320
Telephone(805)447-1000
Fax—
Email—
Websitehttps://www.amgen.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK—
Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firms therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgens biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Additional info from NASDAQ:
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firms therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgens biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

2026-04-22 20:03

(10% Negative) AMGEN INC (AMGN) Announces Delay in patients Development Timeline Due to Geopolitical Situation, Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review

Read more
2026-04-21 18:01

New Form DEFA14A - AMGEN INC <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0000318154-26-000045 <b>Size:</b> 760 KB

Read more
2026-04-15 17:15

New Form DEFA14A - AMGEN INC <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0000318154-26-000040 <b>Size:</b> 741 KB

Read more
2026-04-07 17:26

New Form DEFA14A - AMGEN INC <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001193125-26-145596 <b>Size:</b> 1 MB

Read more
2026-04-07 17:23

New Form DEF 14A - AMGEN INC <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001193125-26-145588 <b>Size:</b> 19 MB

Read more
2026-03-31 10:00

New Form ARS - AMGEN INC <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0000318154-26-000035 <b>Size:</b> 21 MB

Read more
2026-03-26 16:43

New Form SCHEDULE 13G/A - AMGEN INC <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000625 <b>Size:</b> 7 KB

Read more
2026-03-07 00:32

Director Bradway Robert A 🟡 adjusted position in 84.3K shares (1 derivative) of AMGEN INC (AMGN) at $379.27 ($69.4M) Transaction Date: Mar 04, 2026 | Filing ID: 000023

Read more
2026-03-06 01:43

Santos Esteban 🟢 acquired 11.3K shares of AMGEN INC (AMGN) Transaction Date: Mar 03, 2026 | Filing ID: 000022

Read more
2026-03-06 01:42

REESE DAVID M 🟢 acquired 12.1K shares of AMGEN INC (AMGN) Transaction Date: Mar 03, 2026 | Filing ID: 000021

Read more